Changing scenario for promotion and development of Ayurveda – way forward

Contributions to the phytotherapies of digestive disorders: Traditional knowledge and cultural drivers of Manoor Valley, Northern Pakistan

“…inflammation, stomach ache was Xanthium strumarium. Those medicinal plant species having maximum RFC should be further evaluated phytochemically and pharmaceutically to identify their active constituents for drug discovery (Mukherjee et al, 2012;Vitalini et al, 2013). …”

Tyrosinase inhibitory potential of purpurin in Rubia cordifolia—A bioactivity guided approach

“…Combination of ethno-pharmacology information (traditional use) and published scientific studies on plant extracts may be considered as an excellent strategy for lead discovery from medicinal plants. An ethno-pharmacology approach, inspired by Ayurveda and traditional medicine, can emerge as effective strategy to facilitate the discovery process (Mukherjee et al, 2012;Patwardhan and Mashelkar, 2009). Use of purpurin for anti-tyrosinase activity is one of the new findings in this investigation.…”

Currents of Tradition in Sowa Rigpa Pharmacy

“…It is, therefore, proposed to develop an organisation mandated with scientific validation and standardization of Sowa Rigpa to facilitate research in literary, drug, clinical areas and medicinal plants. (AYUSH 2011: 33) Having been left to their own devices for so long, Sowa Rigpa practitioners and institutions must now rapidly adapt to twenty-first-century pressures, including the growing influence of the integrative medicine paradigm (Sujatha 2011), a wave of bioprospecting and patenting of plant-derived knowledge (Dutfield 1999;Mukherjee et al 2012;Patwardhan and Mashelkar 2009), and a "regime of reformulation" in which pharmaceutical firms engage new property rights models to drive hybrid forms of pharmaceutical innovation (Pordié and Gaudilliere forthcoming). Simultaneously defending and transforming Sowa Rigpa in this context (Craig 2012) demand ever closer articulation between various currents of the tradition.…”

“…Traditional production methods are increasingly subject to state-enforced standardization and regulation, such as Good Manufacturing Practices (GMP). Medicinal raw materials, knowledge, and formulas, to patents are being patented and privatized through other forms of commercial intellectual property protection, and medicines are being brought under assessment regimes primarily derived from biomedical notions of quality, safety, and efficacy (Craig 2011(Craig , 2012Dutfield 1999;Mukherjee et al 2012;Saxer 2010). Traditional medicine products are increasingly being shaped, produced, and distributed according to the logics of industry, the capitalist market, and health policy at various levels, further confounding already untenable traditional/modern dichotomies.…”